EX-4.1 3 d62228dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October 31, 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [•] shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), and subject to the following terms and conditions: 1. Definitions. For purposes of this Warrant, the follo…
Open exhibit ↗Current Report · Items 1.01, 8.01, 9.01 · 8-K
Savara Inc.
SVRANASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Other Events
Item 1.01. Entry into a Material Definitive Agreement. On October 29, 2025, Savara Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 23,809,524 shares (the “…
Company context
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Savara’s lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Savara’s management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
Current securities
Recent company filings
- S-8 filingAug 11, 2026
- 10-Q filingAug 11, 2026
- 144 filingJun 22, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersJun 8, 2026
- 10-Q filingMay 12, 2026
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 8.01Item 8.01 - Other Events
Filed exhibits (2)
EX-99.1 5 d62228dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pa., October 29, 2025 - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting discounts and commissions, for total gross proceeds of $130.0 million. All of the securities to be sold in the offering are being sold by Savara. Savara also granted the underwriters a 30-day option to purchase up to an additional 4,642,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 31, 2025, subject to the satisfaction of customary closing conditions. Savara intends to use the proceeds from the offering for general corporate purposes,…
Open exhibit ↗